


Product Name	: Ruxolitinib
Cat. No.	: PC-45872
CAS No.	: 941678-49-5
Molecular Formula	: C ₁₇ H ₁₈ N ₆
Molecular Weight	: 306.365
Target	: JAK
Solubility	: DMSO: ≥ 36 mg/mL; H ₂ O: < 0.1 mg/mL



Biological Activity

Ruxolitinib (INCB-018424) is a potent, selective, orally active **JAK1/JAK2** inhibitor with IC₅₀ of 3.3/2.8 nM, respectively. Ruxolitinib (INCB-018424) displays modest selectivity against Tyk2 (6-fold) and marked selectivity (>130-fold) against JAK3. Ruxolitinib (INCB-018424) inhibits IL-6 signaling (IC₅₀=281 nM), and proliferation of JAK2V617F(+) Ba/F3 cells (IC₅₀=127 nM).

Ruxolitinib (INCB-018424) suppresses erythroid progenitor colony formation from JAK2V617F(+) polycythemia vera patients (IC₅₀=67 nM) in primary cultures.

Ruxolitinib (INCB-018424) markedly reduces level of inflammatory cytokines, and preferentially eliminates neoplastic cells in a mouse model of JAK2V617F(+) MPN.

References

Quintás-Cardama A, et al. *Blood*. 2010 Apr 15;115(15):3109-17.

Fridman JS, et al. *J Immunol*. 2010 May 1;184(9):5298-307.

Verstovsek S, et al. *N Engl J Med*. 2010 Sep 16;363(12):1117-27.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com